CoChat
Sign Up
Cited by 183Brain Metastases and TreatmentCancer Genomics and DiagnosticsGlioma Diagnosis and Treatment

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Open access
Boire, Adrienne, Brandsma, Dieta, Brastianos, Priscilla K, Le Rhun, Emilie, Ahluwalia, Manmeet, Junck, Larry, Glantz, Michael, Groves, Morris D +10 more·2019·Neuro-Oncology
DOI 10.1093/neuonc/noz012PMC PMC6502489
Open this paper in CoChat — free accountOpen PDF

Abstract

Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a surrogate for tumor tissue in the management of both primary and secondary brain tumors. Herein we critically review available literature on spinal fluid and plasma circulating tumor cells (CTCs) and cell-free tumor (ctDNA) for diagnosis and monitoring of leptomeningeal and parenchymal brain metastases. We discuss technical issues and propose several potential applications of liquid biopsies in different clinical settings (ie, for initial diagnosis, for assessment during treatment, and for guidance of treatment decisions). Last, ongoing clinical studies on CNS metastases that include liquid biopsies are summarized, and recommendations for future clinical studies are provided.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noz012

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liquid biopsy as a minimally invasive alternative to traditional imaging and behavioral assessments facilitates ongoing monitoring of biochemical and molecular alterations in the CNS.

    “The utilization of liquid biopsy as a minimally invasive alternative to traditional imaging and behavioral assessments facilitates the ongoing monitoring of biochemical and molecular alterations in the CNS [181–183].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [182]

    The Clinical Applications section (page unavailable) proposes liquid biopsy for monitoring CNS metastases and tracking molecular changes, but describes its use alongside neuroimaging and says prospective studies are needed. It does not present liquid biopsy as an established alternative to imaging or discuss behavioral assessments. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 81 · Cited by 183

Research works printed but not linked: 74

  1. [1]Brastianos PK, Carter SL, Santagata S, et al Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015; 5(11): 1164– 1177. 26410082 PMC4916970
  2. [2]Siravegna G, Marsoni S, Siena S, Bardelli A Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9): 531– 548. 28252003
  3. [5]Connolly ID, Li Y, Gephart MH, Nagpal S The “Liquid Biopsy”: the role of circulating DNA and RNA in central nervous system tumors. Curr Neurol Neurosci Rep. 2016; 16(3): 25. 26838352 PMC8423147
  4. [6]De Mattos-Arruda L, Mayor R, Ng CK, et al Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6: 8839. 26554728 PMC5426516
  5. [7]Pan W, Gu W, Nagpal S, Gephart MH, Quake SR Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015; 61(3): 514– 522. 25605683 PMC5412506
  6. [8]Jiang BY, Li YS, Guo WB, et al Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res. 2017; 23(18): 5480– 5488. 28606923
  7. [9]Chamberlain M, Junck L, Brandsma D, et al Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017; 19(4): 484– 492. 28039364 PMC5464328
  8. [10]Chamberlain M, Soffietti R, Raizer J, et al Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014; 16(9): 1176– 1185. 24867803 PMC4136900
  9. [11]Le Rhun E, Weller M, Brandsma D, et al EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017; 28(suppl_4): iv84– iv99. 28881917
  10. [12]Wasserstrom WR, Glass JP, Posner JB Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982; 49(4): 759– 772. 6895713
  11. [13]van Oostenbrugge RJ, Twijnstra A Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999; 53(2): 382– 385. 10430430
  12. [14]Subirá D, Serrano C, Castañón S, et al Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol. 2012; 14(1): 43– 52. 21993441 PMC3245993
  13. [15]Nayak L, Fleisher M, Gonzalez-Espinoza R, et al Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013; 80(17): 1598– 1605; discussion 1603. 23553479 PMC3662321
  14. [16]Subirá D, Simó M, Illán J, et al Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis. 2015; 32(4): 383– 391. 25795393
  15. [17]Lee JS, Melisko ME, Magbanua MJ, et al Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015; 154(2): 339– 349. 26520840
  16. [18]Tu Q, Wu X, Le Rhun E, et al CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer. 2015; 90(2): 352– 357. 26386833
  17. [19]Milojkovic Kerklaan B, Pluim D, Bol M, et al EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro Oncol. 2016; 18(6): 855– 862. 26566655 PMC4864256
  18. [20]Glantz MJ, Cole BF, Glantz LK, et al Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998; 82(4): 733– 739. 9477107
  19. [21]Patel AS, Allen JE, Dicker DT, et al Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011; 2(10): 752– 760. 21987585 PMC3248154
  20. [22]Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012; 12: 21. 23145812 PMC3539901
  21. [23]Riethdorf S, Fritsche H, Müller V, et al Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3): 920– 928. 17289886
  22. [24]Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol. 2013; 30(2): 538. 23504338
  23. [25]Kraan J, Sleijfer S, Strijbos MH, et al External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom. 2011; 80(2): 112– 118. 21337491
  24. [26]de Wit S, van Dalum G, Terstappen LW Detection of circulating tumor cells. Scientifica (Cairo). 2014; 2014: 819362. 25133014 PMC4124199
  25. [27]Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004; 24(4): 267– 296. 15588226
  26. [28]van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. J Neurooncol. 2018; 137(1): 1– 10. 29192390
  27. [29]Acosta M, Pereira J, Arroz M Screening of carcinoma metastasis by flow cytometry: A study of 238 cases. Cytometry B Clin Cytom. 2016; 90(3): 289– 294. 26054018
  28. [30]Lin X, Fleisher M, Rosenblum M, et al Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol. 2017; 19(9): 1248– 1254. 28821205 PMC5570249
  29. [31]Hyun KA, Koo GB, Han H, et al Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 2016; 7(17): 24677– 24687. 27013581 PMC5029733
  30. [32]Cordone I, Masi S, Summa V, et al Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. Breast Cancer Res. 2017; 19(1): 46. 28399903 PMC5387324
  31. [33]Magbanua MJ, Melisko M, Roy R, et al Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013; 73(23): 7134– 7143. 24142343
  32. [34]Li X, Zhang Y, Ding J, et al Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis. Oncotarget. 2018; 9(2): 2705– 2714. 29416803 PMC5788671
  33. [35]Momtaz P, Pentsova E, Abdel-Wahab O, et al Quantification of tumor-derived cell free DNA (cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016; 7(51): 85430– 85436. 27863426 PMC5356746
  34. [36]Pentsova EI, Shah RH, Tang J, et al Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016; 34(20): 2404– 2415. 27161972 PMC4981784
  35. [37]Marchiò C, Mariani S, Bertero L, et al Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro Oncol. 2017; 19(3): 451– 453. 27838647 PMC5464358
  36. [38]Swinkels DW, de Kok JB, Hanselaar A, Lamers K, Boerman RH Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem. 2000; 46(1): 132– 133. 10620587
  37. [39]Fan Y, Zhu X, Xu Y, et al Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer. Clin Cancer Res. 2018; 24(1): 209– 216. 29030356
  38. [40]Li YS, Jiang BY, Yang JJ, et al Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol. 2018; 29(4): 945– 952. 29346604
  39. [41]Vinayanuwattikun C, Mingmalairak S, Jittapiromsak N, et al SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis). J Neurooncol. 2016; 129(3): 395– 403. 27401153
  40. [43]Shankar GM, Balaj L, Stott SL, Nahed B, Carter BS Liquid biopsy for brain tumors. Expert Rev Mol Diagn. 2017; 17(10): 943– 947. 28875730 PMC5856481
  41. [45]Campos CDM, Jackson JM, Witek MA, Soper SA molecular profiling of liquid biopsy samples for precision medicine. Cancer J. 2018; 24(2): 93– 103. 29601336 PMC5880307
  42. [46]Wang J, Bettegowda C Applications of DNA-based liquid biopsy for central nervous system neoplasms. J Mol Diagn. 2017; 19(1): 24– 34. 27863260
  43. [47]Campos S, Davey P, Hird A, et al Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma. Curr Oncol. 2009; 16(1): 62– 66. 19229374 PMC2644621
  44. [48]Cristofanilli M, Budd GT, Ellis MJ, et al Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8): 781– 791. 15317891
  45. [49]Nagaiah G, Abraham J Circulating tumor cells in the management of breast cancer. Clin Breast Cancer. 2010; 10(3): 209– 216. 20497919
  46. [50]Bidard FC, Peeters DJ, Fehm T, et al Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4): 406– 414. 24636208
  47. [51]Janni WJ, Rack B, Terstappen LW, et al Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res. 2016; 22(10): 2583– 2593. 26733614
  48. [52]Hayes DF, Cristofanilli M, Budd GT, et al Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1): 4218– 4224. 16857794
  49. [53]Zhang L, Riethdorf S, Wu G, et al Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012; 18(20): 5701– 5710. 22908097
  50. [54]Aggarwal C, Meropol NJ, Punt CJ, et al Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013; 24(2): 420– 428. 23028040
  51. [55]Amato RJ, Melnikova V, Zhang Y, et al Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer. Urology. 2013; 81(6): 1303– 1307. 23622774
  52. [56]Garcia-Murillas I, Schiavon G, Weigelt B, et al Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302): 302ra133. 26311728
  53. [57]Beaver JA, Jelovac D, Balukrishna S, et al Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014; 20(10): 2643– 2650. 24504125 PMC4024333
  54. [58]Bettegowda C, Sausen M, Leary RJ, et al Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224): 224ra224. PMC4017867 24553385
  55. [59]Diehl F, Schmidt K, Choti MA, et al Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9): 985– 990. 18670422 PMC2820391
  56. [60]Tie J, Kinde I, Wang Y, et al Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015; 26(8): 1715– 1722. 25851626 PMC4511218
  57. [62]Stover DG, Parsons HA, Ha G, et al Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018; 36(6): 543– 553. 29298117 PMC5815405
  58. [63]Schøler LV, Reinert T, Ørntoft MW, et al Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res. 2017; 23(18): 5437– 5445. 28600478
  59. [64]Balaña C, Ramirez JL, Taron M, et al O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003; 9(4): 1461– 1468. 12684420
  60. [65]Alexander BM, Brown PD, Ahluwalia MS, et al; Response Assessment in Neuro-Oncology (RANO) group. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018; 19(1): e33– e42. 29304360
  61. [66]Fiano V, Trevisan M, Trevisan E, et al MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol. 2014; 117(2): 347– 357. 24519517
  62. [67]Barault L, Amatu A, Bleeker FE, et al Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015; 26(9): 1994– 1999. 26113646
  63. [68]Li Y, Pan W, Connolly ID, et al Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol. 2016; 128(1): 93– 100. 26961773 PMC5412509
  64. [69]Thress KS, Brant R, Carr TH, et al EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90(3): 509– 515. 26494259
  65. [70]Remon J, Menis J, Hasan B, et al The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. Clin Lung Cancer. 2017; 18(5): 583– 588. 28341106
  66. [71]Bardelli A, Corso S, Bertotti A, et al Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013; 3(6): 658– 673. 23729478 PMC4078408
  67. [72]Camidge DR, Pao W, Sequist LV Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11(8): 473– 481. 24981256
  68. [74]Lo RS, Shi H Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. Methods Mol Biol. 2014; 1102: 163– 174. 24258979
  69. [75]Shi H, Hugo W, Kong X, et al Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014; 4(1): 80– 93. 24265155 PMC3936420
  70. [76]Sasaki S, Yoshioka Y, Ko R, et al Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 2016; 54(1): 14– 19. 26718140
  71. [77]Togashi Y, Masago K, Masuda S, et al Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012; 70(3): 399– 405. 22806307
  72. [78]Camidge DR, Lee EQ, Lin NU, et al Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018; 19(1): e20– e32. 29304358
  73. [79]Karachaliou N, Mayo-de las Casas C, Queralt C, et al; Spanish Lung Cancer Group. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015; 1(2): 149– 157. 26181014
  74. [80]Mok T, Wu YL, Lee JS, et al Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015; 21(14): 3196– 3203. 25829397

Authors
Boire, A., Brandsma, D., Brastianos, P. K., Le Rhun, E., Ahluwalia, M., Junck, L., Glantz, M., Groves, M. D., Lee, E. Q., Lin, N., Raizer, J., Rudà, R., Weller, M., Van den Bent, M. J., Vogelbaum, M. A., Chang, S., Wen, P. Y., & Soffietti, R.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • The Netherlands Cancer Institute (NL)
  • Harvard University (US)
  • Department of Neuro-Oncology/Neurosurgery, University Hospital, Lille, France
  • Cleveland Clinic (US)
  • University of Michigan (US)
  • Pennsylvania State University (US)
  • The University of Texas at Austin (US)
  • Brigham and Women's Hospital (US)
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
  • Northwestern University (US)
  • Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
  • University Hospital Zurich (CH)
  • Brain Tumor Center, Erasmus MC Cancer Center and University, Rotterdam, Netherlands
  • University of California, San Francisco (US)
Corresponding author
Boire, Adrienne
ORCID
Venue
Neuro-Oncology
Publisher
Oxford University Press (OUP)
Published
2019-01-22
Volume
21
Issue
5
Pages
571-584
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
DOI
10.1093/neuonc/noz012
PMC
PMC6502489
OpenAlex
W2913626816
Cited by
183
References
81
Citations by year
2026: 17 · 2025: 17 · 2024: 36 · 2023: 27 · 2022: 31 · 2021: 26 · 2020: 21 · 2019: 8
FWCI
3.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuro-Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Institutes of Health (P30 CA008748)
  • NCI Cancer Center
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Keywords
liquid biopsy, central nervous system metastasis, brain metastases, leptomeningeal metastasis, circulating tumor cells, cell-free DNA, cerebrospinal fluid, plasma biomarkers, treatment monitoring, treatment response assessment, clinical trial recommendations
MeSH terms
Clinical Decision-Making, Liquid Biopsy, Circulating Tumor DNA, Humans, Neoplastic Cells, Circulating, Neoplasm Metastasis, Prognosis, Central Nervous System Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review